CA2469821C — Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5

USPTO Abstract

The disclosure relates to a compound which is selected from the group consisting of: 2-[1-(3-chlorophenyl)-1H-1,2,4-triazol-3-yl]pyridine; 3-(3-pyridin-2-yl-1H-1,2,4-triazol-1-yl)benzonitrile; 3 -(1-pyridin-2-yl-1H-1,2,4-triazol-3-yl)benzonitrile; 2-[3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl]pyridine; 3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)benzonitrile; 3-(1-pyridin-2-yl-1H-1,2,3-triazol-4-yl)benzonitrile; 3-(4-pyridin-2-yl-2H-1,2,3-triazol-2-yl)benzonitrile; 3-(4-pyridin-2-yl-1H-1,2,3-triazol-1-yl)benzonitrile; 2-[2-(3-chlorophenyl)-2H-1,2,3-triazol-4-yl]pyridine; 2-[1-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]pyridine; 2-[2-(3,5-difluorophenyl)-2H-1,2,3-triazol-4-yl]pyridine; 2-[1-(3,5-difluorophenyl)-1H-1,2,3-triazol-4-yl]pyridine; 2-{2-[3-fluoro-5-(pyridin-2-yloxy)phenyl]-2H-1,2,3-triazol-4-yl}pyridine; 2-{1-[3-fluoro-5-(pyridin-2-yloxy)phenyl]-1H-1,2,3-triazol-4-yl}pyridine; 2-{4-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-1,2,3-triazol-2-yl}pyridine; 2-{4-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-1,2,3-triazol-1-yl}pyridine; 2-[4-(3-cyanophenyl)-2H-1,2,3-triazol-2-yl]nicotinotrile; 3-[2-(5-nitropyridin-2-yl)-2H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(5-nitropyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(3-nitropyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile; 3-[2-(3 -nitropyridin-2-yl)-2H-1,2,3-triazol-4-yl]benzonitrile; 3-[1-(5-aminopyridin-2-yl)-1H-1,2,3-triazol-4-yl]benzonitrile hydrochloride; N-[3-(1-pyridin-2-yl-1H-1,2,3-triazol-4-yl)phenyl]pyridin-3-amine; N-[3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)phenyl]pyridin-3-amine; 3-(2-pyridin-2-yl-1H-1,2,3-triazol-4-yl)phenol; and 3-(2-pyridin-2-yl-2H-1,2,3-triazol-4-yl)phenol; or a pharmaceutically acceptable salt thereof which are metabotropic glutama te receptor - subtype 5("mGluR5") modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease , cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abus e, drug withdrawal and other diseases. The disclosure further relates to a pharmaceutical composition containing said compounds and their uses thereof.